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Abstract
Background: Regenerative strategies of stem cell grafting have been demonstrated to be effective in animal models of
stroke. In those studies, the effectiveness of stem cells promoting functional recovery was assessed by behavioral testing.
These behavioral studies do, however, not provide access to the understanding of the mechanisms underlying the observed
functional outcome improvement.
Methodology/Principal Findings: In order to address the underlying mechanisms of stem cell mediated functional
improvement, this functional improvement after stroke in the rat was investigated for six months after stroke by use of fMRI,
somatosensory evoked potentials by electrophysiology, and sensorimotor behavior testing. Stem cells were grafted
ipsilateral to the ischemic lesion. Rigorous exclusion of spontaneous recovery as confounding factor permitted to observe
graft-related functional improvement beginning after 7 weeks and continuously increasing during the 6-month observation
period. The major findings were i) functional improvement causally related to the stem cells grafting; ii) tissue replacement
can be excluded as dominant factor for stem cell mediated functional improvement; iii) functional improvement occurs by
exclusive restitution of the function in the original representation field, without clear contributions from reorganization
processes, and iv) stem cells were not detectable any longer after six months.
Conclusions/Significance: A delayed functional improvement due to stem cell implantation has been documented by
electrophysiology, fMRI and behavioral testing. This functional improvement occurred without cells acting as a tissue
replacement for the necrotic tissue after the ischemic event. Combination of disappearance of grafted cells after six months
on histological sections with persistent functional recovery was interpreted as paracrine effects by the grafted stem cells
being the dominant mechanism of cell activity underlying the observed functional restitution of the original activation sites.
Future studies will have to investigate whether the stem cell mediated improvement reactivates the original representation
target field by using original connectivity pathways or by generating/activating new ones for the stimulus.
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Introduction
Stroke is a leading cause of mortality and the main cause of
morbidity in developed countries. Thrombolysis is the only
effective treatment to restore blood flow and preserve brain
function, accepted in the clinic. However, this treatment presents
serious safety-related restrictions so that its use is limited to a very
small fraction of all stroke patients (less than 3%) [1].
On the other hand, the brain has the potential to spontaneously
resolve stroke-related functional deficits. Although the exact
mechanisms are not known, among the discussed possibilities are
activation of alternative, already existing neuronal networks,
rewiring of new circuits, plastic reorganizations, or also promoting
tissue repair by endogenous stem cells. Unfortunately, these
aspects are not understood and are often not sufficient to
compensate the severe damage inflicted by the stroke. With the
recent fast progress of stem cell biology, high expectations are set
in the use of growth factors and stem cell-based therapies [2] to
promote functional recovery after brain damage. Regenerative
therapies have, indeed, been demonstrated to be effective in
several experimental studies of animal models of stroke [3–9].
Most of these published studies have assessed the effectiveness of
stem cells promoting functional recovery by behavioral testing.
Despite the undoubted contribution of these investigations, the
behavioral studies do not provide access to the understanding of
the mechanisms underlying the observed functional outcome
improvement. For a causally based therapy optimization the
potentially contributing mechanisms, i.e. integration of implanted
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neuronal tissue by paracrine activity, must be recognized and
discriminated. Furthermore, it is of high importance to understand
the mechanism by which the therapeutic effect of the stem cell
activity acts: i.e. recovery enhancement, induction of plastic
reorganization or even transhemispheric compensation are all
options, explaining a functional improvement as observed by
behavior patterns.
Then, the following two major questions arise: i) do the stem
cells execute their beneficial effect by tissue integration or rather
by paracrine effects; and ii) which mechanism, activated by the
cells’ therapeutic activity, explains the functional improvement:
recovery of the original representation field or plastic reorganiza-
tion? To address these two questions, we have decided to
investigate stem cell mediated functional improvement by use of
a non-invasive imaging technique, in particular functional
Magnetic Resonance Imaging (fMRI), which allows to detect,
localize and characterize activated cortical representation fields to
a specific sensorimotor stimulus. Additionally, this strategy has the
immense advantage to follow both, lesion evolution and functional
deficit, followed by later functional improvement, in individual
subjects in a longitudinal manner, rather than to rely on cross-
sectional studies with multiple subjects at different time points.
Taking these considerations into account, we have designed and
performed a longitudinal study of stem cell mediated functional
recovery after stroke, using a well-established experimental model
of ischemic stroke, together with a protocol for longitudinal
functional assessment of individual animals by combined use of
fMRI, somatosensory evoked potentials (SSEPs) and sensorimotor
behavioral testing, over a period of 6 months after ischemic lesion
induction and stem cell implantation [10–11].
The same experimental protocol was used in the past to
characterize spontaneous functional recovery after stroke [10].
This fact helped us in the present investigation to separate
spontaneous functional improvements from those achieved only by
the presence of stem cells in the cerebral parenchyma.
Our data will show that, when proper conditions for cell-based
therapy success are fulfilled, it is possible to claim that stem cells do
effectively promote functional recovery after stroke.
Results
Protocol of Animal Selection for the Treatment Study
A total of 51 animals entered the longitudinal study, depicted in
Fig. 1, and were submitted to middle cerebral artery occlusion
(MCAO). Sixteen of them died either during surgery or during the
first 48 h, most probably as a consequence of massive edema with
swelling of the affected hemisphere and compression of the
unaffected hemisphere. Among the survivors (n=35) from this
acute phase, the extension of the ischemic lesion was studied at
48 hours after MCAO by calculating T2 maps from the spin-echo
MR images. In a previous fMRI study using the same
experimental model, we had already shown that lesions, restricted
to the caudate-putamen of the brain and not affecting cortical
areas, resulted in animals with no loss or just a transient loss of
functional brain activity. This activity was then spontaneously
recovered 2–3 weeks after MCAO for all subjects with only striatal
lesions [10]. Accordingly, to avoid confounding effects from
spontaneous recovery processes on stem cell treated animals, those
animals with an exclusively striatal lesion but intact cortex on T2
maps, were excluded from our study at this point, 48 h after stroke
induction (20 animals excluded, 39% of the total n=51 and 57%
of the 35 survivors) (see Fig. 2).
The remaining 15 animals with cortico-striatal lesions underwent
an fMRI study 18–20 days later (i.e. 3 weeks after MCAO). The
period of 3 weeks before the fMRI was established again in
accordance with the previously reported results of the study of
spontaneous functional recovery following stroke [10]. There, it was
stated that 3 weeks after stroke induction can be considered the
earliest, safe time point to discriminate animals with spontaneous
recovery of brain activity from those with permanent loss of
functional activity (defined as absence of any BOLD signal in fMRI
studies and as absence of electrical activity registered on somatosen-
sory evoked potentials over the S1FL areas of the cortex) [10].
Therefore, and according to our earlier established discrimina-
tion criteria, only those animals without fMRI over the ischemic
hemisphere at 3 weeks after MCAO were included for therapeutic
intervention of stem cells, thus safely excluding confounding
interferences from naturally-occurring spontaneous processes.
Seven of the 15 animals assessed at week 3 (47% of the group of
15, 14% of the total n=51) had regained electrical activity and a
BOLD signal and were therefore excluded from the stem cell
implantation study.
The remaining 8 animals (53% of the 15 included ones, and
17% of the total n=51 animals at the beginning of the study) were
unambiguously suitable for therapeutic studies. The whole sorting
process of the animals from the beginning of the study up to this
point is presented in Fig. 2.
Stem Cell Implantation
The group of n=8 animals, suitable for the study, was
randomly split into two groups of n=4 animals, group I to be
treated with stem cells, and group II to be used as untreated
control stroke group.
Three weeks after occlusion of the MCA, and one day after the
fMRI-based discrimination experiment, animals of group I (n=4)
Figure 1. Time schedule of the experimental procedures. BT: behavioral testing, CSP: Cyclosporin application, fMRI: functional MRI study,
Hst: histology, MCAO: middle cerebral artery occlusion, i.e. stroke induction, MRI: 3D high-resolution T2*-weighted MRI, SC: stem cell implantation,
Sfc: sacrifice, W: week.
doi:10.1371/journal.pone.0012779.g001
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of them labeled with iron oxide nanoparticles. Cell labeling was
performed to ensure the accurate and successful positioning of the
cells into the brain parenchyma, by acquiring T2*-weighted MR
images directly following the implantation process (Fig. 3).
Labeling was intentionally restricted to only 10% of all cells to
Figure 2. Selection process of the animals for the treatment inclusion. Animals were selected according to the outcome from the MCAO
surgery (only subcortical vs. cortico-subcortical lesions) and the fMRI study performed at week 3 (regained vs. non-regained BOLD activation). Finally
the remaining animals were randomly asigned to a control and a stem cell-treated group. Gray boxes indicate animals excluded from further
procedures at each time point, while white boxes indicate the animals selected for successive stages of the study.
doi:10.1371/journal.pone.0012779.g002
Figure 3. Localization of labeled cells by T2*-weighted MRI. 3D high resolution T2*-weighted MR images, pre- (1st column) and post- (2nd
column) implantation of USPIO-labeled stem cells, showing the successful implantation of the cells into the brain parenchyma. Corresponding T2-
weighted images (3
rd column) confirm that cells were implanted in healthy tissue.
doi:10.1371/journal.pone.0012779.g003
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alterations of their viability or cell characteristics, which could
originate from the presence of the iron depots of the label in the
cytoplasm. Cells were injected into healthy tissue, ipsilaterally and
close to the lesion border, at a position caudal to bregma. The
exact implantation coordinates varied among animals as they
depended on the extension of the ischemic lesion of each
individual, assessed on T2 maps obtained from T2-weighted
MR images (Fig. 3).
Bold Functional Imaging
Both groups of animals (with and without stem cell implanta-
tion) were studied for a period of 6 months (24 weeks) after the
ischemic insult, using a well-established non-invasive longitudinal
fMRI protocol [10–11]. A temporal profile of the acquired BOLD
activation in the somatosensory cortex is presented for 4 of the
total 8 studied animals (2 implanted and 2 controls) in Fig. 4. None
of the animals from the control group (II) recovered any sign of
BOLD signals in the affected (right) hemisphere, while stable
BOLD signals persisted throughout the whole study in the primary
somatosensory representation field of the forepaw (S1FL) of the
unaffected (left) hemisphere (Fig. 4, top rows). This result reaffirms
the validity of the ‘‘sorting point’’ established at week 3, and
previously reported results [10].
For the treated group (I), all animals showed a regular BOLD
signal in the unaffected (left) hemisphere throughout the 6 months
observation period. 2 of the 4 animals started to present signs of
BOLD signals in the affected (left) hemisphere starting from weeks
10 to 14 after MCA occlusion (weeks 7–11 after implantation of
cells). Activation was always observed at the original representa-
tion field of the forepaw in the sensorimotor cortex (S1FL), and no
signs of plastic reorganization were observed on those brains
(Fig. 4, lower rows). In one of these two animals, a transient BOLD
signal was observed at week 20 in the healthy (left) hemisphere,
when stimulating the left (ipsilateral) paw (Fig. 4, treated animal
#2, week 20).
Relation between Lesion Extent and Functional Recovery
In Fig. 5, T2 maps are presented documenting the extent of the
lesion for all 8 studied animals (groups I and II). The MR images
were superimposed with a map of the different anatomical regions
of that section of the brain, taken from the anatomical atlas for the
rat brain by Paxinos and Watson [12]. In those images, the S1FL
area ipsilateral to the affected hemisphere, was spared from the
ischemic lesion for the two treated animals that recovered BOLD
activity (animals 1 and 2 of group I), while the S1FL area was
actually part of the damaged tissue area in the case of the two
animals not recovering activity (animals 3 and 4 of the treated
group I in Fig. 5). Therefore, these latter 2 implanted animals had
no chance to recover function, since the original representation
field of the forepaw was destroyed by the ischemic lesion.
BOLD signals were quantified to obtain both, the percentage of
signal intensity change during stimulation, and the extent of the
activated brain volume in cubic millimeters. Results are presented
in Fig. 6. For the healthy (left) hemisphere, all 8 animals presented
similar values for both, BOLD signal intensity (mean6SD across
all fMRI sessions; 3.4360.15% for the control group vs
3.5660.07% for the treated group) and activated volumes
Figure 4. Functional brain recovery during six months observation. BOLD images obtained during the 24 weeks exploration period for two
control animals (top rows), presenting a permanent loss of BOLD signal on the affected right hemisphere, and the two stem cell implanted animals
(bottom rows) that regained BOLD activity at the affected hemisphere starting from week 10.
doi:10.1371/journal.pone.0012779.g004
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3 for the
control group vs 9.5761.42 mm
3 for the treated group). Results
were not significantly different at a level of p,0.01. Values for the
affected (right) hemisphere in the fMRI session prior to MCA
occlusion (3.2760.21% and 5.2862.16 mm
3 for control group II
vs 3.2060.05% and 7.5261.20 mm
3 for the treated group I) were
not significantly different from the results of the left hemisphere.
On the affected (right) hemisphere, no activity was detected on
BOLD images for any animal of the control group, at any time-
point of the 6 months observation period, as well as for those two
animals implanted with stem cells but with the ischemic lesion
directly affecting the S1FL area of the brain.
The two animals of the treated group, with the original
representation field of the forepaw spared from the ischemic
lesion, showed a BOLD response starting from week 10 after
lesion induction (week 7 after implantation) for one of them and
from week 14 (week 10 post implantation) for the other one. The
mean value of the BOLD signal intensity for the affected (right)
hemisphere over this period (weeks 10–24) was 2.460.86%, which
is not significantly different from the values obtained for the
healthy hemisphere, and from the pre-stroke scans on both brain
hemispheres (cf. above). But activated representation volumes
continuously increased during the observation period from
1.7662.49 mm
3 (week 10) to 3.0462.16 mm
3 (week 24). These
values were significantly different, except for week 24, from pre-
stroke values, or from values of the healthy (left) hemisphere for all
time points, at a significance level of p,0.05.
Thus, treated animals which preserved an intact appearing
original representation field of the forepaw, regained brain activity
in that area, starting 7–11 weeks after implantation of stem cells,
with the same intensity as prior to the lesion, but starting recovery
in a significantly smaller volume which then continuously grew
over time, without having (yet) reached normal values at the end of
the 6 month observation period.
Electrophysiology
During all fMRI sessions, somatosensory evoked potentials were
recorded over the S1FL areas of both forepaws with subcutane-
ously implanted electrodes over the intact skull of the rats (Fig. 7).
No significant differences were observed for the amplitudes of
SSEP signals recorded over the healthy (left) hemisphere of all 8
animals in all fMRI sessions (42.068.6 mV for treated group vs
59.7610.6 mV for the control group), or the affected (right)
hemisphere in the pre-stroke scan (26.266.7 mV for treated group
vs 45.7619.1 mV for the control group). For the untreated group,
as well as for the two treated animals that had presented with an
ischemic S1FL, no SSEP signals were detected at any of the
sessions after MCA occlusion, confirming the absence of BOLD
signal during those sessions. On the other hand, small but
significant SSEP signals (3.6465.14 mV) were detectable 4 weeks
after implantation of stem cells (week 7 after MCAO). This return
of electrical activity thus appeared 3 weeks earlier than the first
time a BOLD response was achieved in the lesioned brain
hemisphere. Those values increased continuously until week 14,
when a value of around 10 mV (half of the value at the pre-stroke
scans) was achieved. Then, this amplitude did not increase further
but persisted for the following sessions (mean6SD of 8.9862.3 mV
for sessions at weeks 14, 20, 22 and 24).
Behavioral Testing
Behavioral tests of adhesive tape removal from the paw were
performed for all animals always the day before the fMRI session,
and were preceded by 3 training sessions before animals were
submitted to MCA occlusion. Results are presented in Fig. 7.
At base-line level, animalscontacted the tape atvery shortlatency
times for both, the right paw (control group: 2.561.3 s vs treated
group: 1.860.63 s) and the left paw (control group: 7.661.8 s vs
treated group: 3.561.6 s). Results were not significantly different at
a level of p,0.01.
For the unaffected (right) limb, controlled by the healthy (left)
side of the brain, contact times remained at the same level for both
groups during the whole 6 months observation period (control
group: 2.961.2 s vs treated group: 1.760.9 s).
For the left forepaw, controlled by the affected (right)
hemisphere of the brain, times to contact the tape were
dramatically increased and ranged between 61.0643.6 s at week
3 after stroke to 47.9650.6 s at week 24, with a mean value of
53.1645.0 s over the observation period of 6 months. The two
animals that received stem cells, with ischemic S1FL area, also
presented large behavioral deficits, and the corresponding contact
times (ranging from 60.268.7 s at week 3 to 24.5614.8 s at week
24, with a mean value of 42.1636.3 s) were not significantly
different from those obtained for the (untreated) control group. For
the two animals that received stem cells, and where the S1FL area
was not directly affected by the ischemic lesion, latency times
ranged from 24.0612.7 s at week 3 to 18.268.7 s at week 24, with
a mean value of 35.0626.1 s. We would like to point out the
Figure 5. Spread of ischemic lesion. T2 maps of the 4 control (top)
and 4 stem cell implanted (bottom) animals used in our study. The
corresponding coronal sections of the Paxinos and Watson atlas of the
rat brain [12], with the key brain region S1FL shadowed, have been
superimposed in each image, showing that animals labeled as 3 and 4
for each group presented lesions that include this region of the cortex,
while in the others (animals 1 and 2 of each group) the S1FL region is
not affected.
doi:10.1371/journal.pone.0012779.g005
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the day before stem cell implantation), which does not match with
the much higher values obtained for the same animals at week 5
(65.8659.2 s) or week 7 (46.9640.4 s). This result is most likely
due to the fact that, at this phase of the study, the number of
animals per group is limited, and differences on the performance
of one single animal at a particular session have large influence on
the mean values, as stated by the high standard deviations of each
mean. Although the mean value of the treated group did not reach
a significant difference relative to the control group at any time
point (at a level of significance of p,0.01), a trend toward a better
behavioral performance of the treated animals, particularly from
week 14 on to the end of the observation period, is clearly visible in
Fig. 7.
Histology
At the end of the study, 21 weeks after stem cell implantation,
no trace of the implanted, b-galactosidase positive cells was
observed on histological sections, and only traces of the iron load
of the 10% labeled cells was found at the injection site (data not
shown). Substantial integration of grafted stem cells into the
periphery of the ischemic tissue was definitely not observed.
Discussion
Experimental studies using stem cell implantation to treat stroke
have mostly focused on the hypothesis of cell replacement
mechanisms, i.e. the repair of damaged tissue for the recovery of
lost functions. In vivo cell tracking experiments were designed to
follow the fate of such cells after implantation, demonstrating that
cells are able to survive, migrate, differentiate and integrate into
existing neuronal networks [13–19]. Lately, however, it has been
accepted that implanted cells do not have to integrate into existing
neuronal networks, or repair damaged networks, but that their
presence can already induce endogenous mechanisms of tissue
repair and brain plasticity, by means of a paracrine activity like,
for example, releasing trophic factors [5–6,20–22]. The impor-
tance of these two different mechanisms for functional recovery
after stroke mediated by the therapeutic intervention of stem cells
is not completely known.
The effectiveness of stem cells to enhance functional recovery
after stroke has been regularly reported during the last decade in
the literature [4,7–8,23–31]. However, the positive results of these
investigations were based on behavioral tests to assess the extent of
regained functional activity, while the studies do not provide
insight into the physiological mechanisms underlying the obser-
vations of outcome improvement.
It was the goal of the present study to elucidate the mechanism
dominantly responsible for the observed functional outcome. For
this purpose, we performed, for the first time, a longitudinal
follow-up investigation on stem cell-mediated functional recovery
after stroke by using functional neuroimaging tools, reinforced by
the use of behavioral testing and measurements of electrical brain
activity.
The major findings of our present study were: 1) Untreated,
ischemic rats, included according to our rigorous selection criteria
(cf above), did not demonstrate any spontaneous recovery process,
neither by electrical activity criteria of SSEPs, neither by fMRI nor
Figure 6. Quantitative analysis of fMRI data during recovery. Top row, percent change of signal intensity (BOLD effect) during stimulation of
the forepaw (mean value 6 standard deviation) for the healthy (left plot) and affected (right plot) hemispheres of the brain, for the control group
(white bars), and for the two animals treated with stem cells that regained BOLD signal in the affected hemisphere (dark gray bars). Bottom row,
activated volume (in mm
3) in the primary somatosensory cortex in the healthy (left) and affected (right) hemispheres.
doi:10.1371/journal.pone.0012779.g006
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into the ischemic periphery to form a new neuronal network but
were lost after 6 months despite persistent functional improve-
ment. 3) Functional improvement is causally related to the grafting
of stem cells. Return of electrical activity and fMRI signal in
response to the forepaw stimulation was observed exclusively in
stem cell treated animals. This return of activation in the original
representation field was accompanied by an ongoing behavioral
improvement pattern. 4) Stem cell mediated functional improve-
ment was achieved exclusively through recovery of the original
representation field. 5) There was no plastic reorganization either
to an adjacent cortical area or even to the contralateral
hemisphere of all animals studied, stem cell treated and untreated.
Only in a single case and at one time point, we observed a shift of
the activation field to the contralateral hemisphere, but this had
shifted back already during the next study time point.
In sum, these observations lead us to conclude that the
dominant reason for the observed return of functional activation
several weeks after stem cell implantation must lie in the cells’
contribution of a paracrine effect to the brain’s own efforts for
restitution of lost functions. This is in full agreement with several
earlier reports of stem cell mediated outcome improvement where
the authors interpreted their results as predominantly due to
paracrine effects [5–6,20–22].
Animal Inclusion Criteria
After a thorough process of ‘‘animal screening’’, based on
anatomical and BOLD-fMRI data, we were able to distinguish
and sort out those animals that would spontaneously regain
functional activity in the affected brain hemisphere. Thus, all
animals that passed through our ‘‘screening filter’’ did not
spontaneously regain BOLD signal for a period of 6 months.
This selection drastically reduced the number of animals in our
study to a small fraction of the initial pool of animals (8 out of 51),
but in return provided us with a rigorous protocol guaranteeing
highly reliable data of the mechanisms behind the therapeutic
effect of stem cells in the brain, while safely excluding naturally
occurring, but confounding functional restoration processes.
Paradoxically, the extremely rigorous inclusion criteria used in
this study constitutes one of its greatest strengths and, at the same
time, its biggest limitation. From the initial 51 animals submitted
to surgery, only 8 remained though the whole study, because we
succeeded in separating confounding effects of spontaneous and
stem cell-mediated processes of functional recovery after stroke.
To our knowledge, there are no reports in the literature that have
addressed this issue, while our data and conclusions are free of
interferences caused by naturally occurring processes. This is a
major strength of the present investigation. On the other hand, the
validity of our conclusions may be hampered by the fact that only
two groups of four animals each remained at the end of the study.
The low number of animals per group in this study must be seen as
a clear limitation and further work is warranted to confirm our
results in larger groups of animals.
It should, however, also be emphasized in support of the study
that the provision of the whole time profile for each individual
during the longitudinal study is a po t e n ta s p e c ta si tr e d u c e st h e
Figure 7. Quantitative analysis of electrophysiologic data during recovery. Top row, Amplitude (in mV) of the somatosensory evoked
potentials detected over the S1FL cortical area of the brain, acquired during the fMRI sessions. Bottom row, result of the sticky tape behavioral test.
Time to contact the tape stuck to the forepaws of the animals is presented (mean 6 standard deviation, in seconds). As in Fig. 4, the plots present the
data for the control group (white bars), and for the group of animals treated with stem cells that recovered BOLD signal (dark gray bars).
doi:10.1371/journal.pone.0012779.g007
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study time point. Considering that in this investigation post-
stroke fMRI alone has been performed at eight time points on
eight animals, this would be equivalent to 64 animals needed for
eight cohorts during invasive, one-time-point studies. Further-
more, the time profiles provide a quality of individual response
characteristics otherwise not accessible with invasive studies of
cohort comparisons.
Time Line of Functional Recovery
Our ‘‘spontaneous-recovery-free’’ data clearly emphasize that the
functional improvement of animals treated with stem cells after stroke
does not take place on short term, but takes time before the
therapeutic effect becomes detectable. This finding is in agreement
with previously published works that depict a delayed action of
implanted stem cells [32]. During the first 4 weeks after implantation
no signs of recovery were observed. Then, animals started to show a
progressive improvement that included re-appearance of electrical
activity on the affected somatosensory cortex (weeks 4 to 7 post
implantation), regaining of BOLD signal (weeks 7 to 10 post
implantation) funneling into a robust response to stimulation in fMRI
studies (21 weeks postimplantation), but without yet reaching normal
levels of activity at the end of the 6 month observation period.
A strong point of this study is that behavioral tests performed to
assess functional outcome, electrical activity reflected in measured
evoked potentials, and hemodynamic data from BOLD-based
fMRI studies, were all well correlated and in agreement with
previously reported data. In general, all point to the fact that some
level of electrical activity starts to show up a few weeks before
BOLD signal is regained, while behavioral tests do not completely
reflect those effects, since compensatory mechanisms can induce a
better-than-expected performance of the animals [10].
Mechanisms of Functional Improvement
Reorganization versus recovery of original representa-
tion field. From a mechanistic point of view, our data confirm
that, for this particular experimental model of stroke, stem cell
mediation of functional recovery from stroke (as detected by SSEP
and BOLD fMRI data) is associated with return of activity to the
original representation field of the affected limb in the somatosensory
cortex, while no plastic reorganization of the brain was observed in
any of the 8 studied animals for the whole observation period of 6
months (except for a transitory effect for one single animal at a
particular time point, already mentioned above). Our findings are in
full agreement with literature, since we were not able to find a single
report that supported the idea of stem cells inducing plastic
reorganization after stroke. Furthermore, the present finding is
extending the earlier report that already spontaneous recovery in this
stroke model is exclusively taking place by reactivating the original
representation field in the S1 cortex [10].
Cell replacement versus paracrine effects. We were not
able to find implanted cells on histological sections (we only detected
iron from that labeled 10% fraction of the implanted cells) at 6 months
after their implantation, while at the same time monitoring a robust
and continuously increasing functional improvement. There was
definitely no neuronal network formation by the grafts observed. This
lead us to speculate that the stem cells must have mediated functional
recovery via a paracrine activity after implantation. Potential aspects
could be release of growth factors, modulation of the immune response
and enhancement of endogenous neurogenesis, rather than direct
integration of the grafted cells into existing neuronal networks and their
participation in processes of tissue repair. Although a better
understanding is needed about the specific mechanism of such a
paracrine effect, the present conclusions are in full agreement with
earlier reports by several other laboratories, also showing paracrine
effects [5–6,20–22] as the most likely reason for observed behavioral
outcome improvements. Survival of implanted stem cells, as was
argued in those earlier reports, was not a prerequisite for efficacy, since
the stem cells may be involved in paracrine activity early after
implantation, and disappear after longer periods of time [22,32–33].
A potentially occurring immune response to the cells after
cessation of the immune suppression treatment with cyclosporin,
must also be considered responsible for the absence of any trace of
the implanted cells (of murine origin) at the end of the study. The
loss of a considerable fraction of cells with time after suppression of
immunologic treatment has already been addressed by other
authors [33], but the fact that we continued immune suppression
for a period of three weeks after stem cell implantation, appears to
possibly have been a sufficient time period to allow paracrine
effects to take place in therapeutically relevant and detectable
extent. Nevertheless, we can not exclude that a more extended
period for the immune suppressing treatment could have
generated further therapeutic effects of the cells.
Finally, it should be mentioned that the here reported findings
may be, to some extent, dependent on the used experimental
stroke model and on the cell lineage chosen for treatment. While
the intraluminal occlusion of the middle cerebral artery in the rat
is one of the most used and validated experimental models of
stroke with high clinical relevance, the selection of the C17.2
lineage of cells, a clonal multipotent neural precursor cell line
originally derived from the external germinal layer of neonatal
mouse cerebellum [34–35] was based on their reported good
therapeutic effects in animal models of brain damage including
stroke [36–38]. In a recent report of a regeneration model of spinal
cord injury, the same C17.2 murine neural progenitor cell line as
used in our study, was grafted into the lesion [39]. Those authors
described a strong secretion by the C17.2 cells of the growth
factors NGF, BDNF, and GDNF as the reason for their
observation of axonal sprouting of endogenous cells and of the
clear outcome improvement [39]. This report of a therapeutically
relevant paracrine effect of the C17.2 cells is in full support of our
present finding that these cells have not integrated but have,
nevertheless, induced an unambiguous functional improvement.
Further studies will be required to investigate to what extent
other cells can possibly participate in one or both of the discussed
mechanisms after implantation (i.e. tissue repair vs. paracrine
activity), depending on different experimental conditions.
Conclusions
The careful exclusion of spontaneous improvement in our
experimental protocol has provided unequivocal demonstration of
stem cell-mediated functional improvement of the rat brain after
stroke, as a consequence of stem cell grafting. The dominant
mechanism of functional recovery is restitution of the activation of
the original representation, without pronounced, detectable
contributions from reorganizational processes. This functional
restitution appears to be achieved primarily through paracrine
activities of the grafted cells which have disappeared after several
months despite persisting functional improvement. Due to the
rigorous selection principle, the results have become extremely
stable and reliable. But the resulting small sample number
warrants further such complex longitudinal studies to confirm
the present conclusions.
Materials and Methods
All animal experiments were performed in accordance with the
European Union’s animal protection guidelines, and were
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Verbraucherschutz Nordrhein-Westfalen) under permission num-
ber 9.93.2.10.31.07.048 (dated 22.05.2007).
Animals
51 male Wistar rats (Harlan-Winkelmann, Borchen, Germany)
were used, with a weight of 308623 g at the beginning of the
study. Animals were kept on a 12/12 hours light/darkness cycle,
with access to food and water ad libitum.
Ischemic stroke model
The ischemic lesion was induced by transient (60 minutes)
occlusion of the right middle cerebral artery (MCAO), using the
intraluminal thread occlusion method, described elsewhere [10].
The occlusion period and the successful reperfusion of the right
MCA were controlled by continuous recordings of ipsilateral laser-
Doppler flowmetry (LDF).
Anesthesia
During all surgical procedures, anesthesia was achieved with
halothane (1.5–2%) in a gas mixture of O2:N2O (35%:65%). For
fMRI studies, a medetomidine-based anesthesia protocol was used
as described before [10–11].
Stem cells
C17.2 cells, a clonal multipotent neural precursor cell line
originally derived from the external germinal layer of neonatal
mouse cerebellum [34–35], were cultivated in DMEM containing
15% FCS, non-essential amino acids (stock solution 1:100),
penicillin-streptomycin (stock solution 1:100), mercaptoethanol,
and leukemia inhibitory factor (100 nM). 10% of the cells were
labeled with the iron-based MRI contrast agent SINEREM
(generous gift of C. Corot, Guerbet, France), using a lipofecting
reagent (FuGENE, Roche) [14]. 500.000 cells were injected into
healthy tissue (as determined on T2-weighted MR images),
ipsilateral to the lesion and at a position caudal to Bregma,
depending on the axial extension of the ischemic lesion. The
successful implantation of cells was confirmed by high resolution
T2*-weighted MRI, with contrast created by the labeled 10% of
the implanted cells. Cells were b-galactosidase positive, in order to
be traceable in histological studies.
Immunosuppression
To avoid an immune response to the implanted cells (from
murine origin) in the rat, 25 mg/kg body weight of Cyclosporin A
(Novartis) solved in castor oil (1 ml), was intradermally adminis-
tered once every 2 days, starting on day 2 before stem cells
implantation, and continued for 3 weeks.
Immunohistochemistry
Animals were sacrificed after the last fMRI scan (week 24) under
deep anesthesia and transcardially perfused with PBS and 4%
paraformaldehyde (PFA). Brains were removed and postfixed
overnight in 4% PFA, followed by immersion in a 30% sucrose
solution for 3 days for cryo-protection, and stored at 280uC until
further processing. Coronal 40 mm-thick sections were cut on a
freezing microtome (Leica, Nussloch, Germany) and stored free-
floating at 4uC. Prussian Blue iron staining was achieved by treating
the tissue sections with 20% hydrochloric acid and 10% potassium
ferrocyanide, trihydrate (Sigma-Aldrich). b-galactosidase staining of
the Lac-Z positive injected stem cells was performed by treating the
tissue sections with X-Gal, dissolved in DSMO, together with
potassium ferrocyanide (Sigma-Aldrich). All tissue sections were
analyzed and digitally photographed using Leica MZ FL III and
Leica DM RB microscopes, both equipped with CCD cameras.
Lesion follow-up
fMRI experiments were performed 1 week before and 3, 5, 7,
10, 14, 20, 22 and 24 weeks after stroke induction. Lesion anatomy
was assessed using T2 maps generated from spin-echo images
acquired on day 2 after MCA occlusion, and on all fMRI sessions.
High resolution 3D T2*-weighted images were acquired on week
3, one scan before (control) and one after the injection of iron-
loaded stem cells, and at 6, 8, 9, 13 and 24 weeks after MCAO. A
schematic representation of the experimental protocol performed
for each individual animal is presented in Fig. 1.
MRI
Experiments were conducted on a 7T horizontal bore magnet
(BioSpec, Bruker BioSpin, Ettlingen, Germany), equipped with
actively shielded gradient coils (20 cm diameter, 200 mT/m).
Radiofrequency transmission was performed with a home-built
Helmholtz coil (12 cm diameter); signal was detected using a
2.2 cm circular surface coil, positioned over the head of the
animal. The animal was fixed in a stereotaxic holder with teeth
bar, earplugs and adhesive tape. Both, transmission and reception
RF coils, were actively decoupled from each other.
Lesion characterization
Lesion characterization, concerning size and status, was
achieved using T2 maps which had been calculated from a set
of multi-slice multi-echo (MSME) spin echo images: 16 echoes
with TE/TR=7.5/2000 ms, 16 slices of 1 mm thickness, FOV of
32632616 mm
3
covered by a 1286128616 matrix, resulting in
an in-plane resolution of 250 mm.
Cell implantation success
Cell implantation success was stated from high resolution 3D
T2*-weighted images using a 3D-FLASH sequence, with a flip
angle of 30 degrees, TE=20 ms, TR=200 ms, a FOV of
20620610 mm
3 covered by a 1606160640 points matrix, zero-
filled to 2566256664 points to give a nominal resolution of
786786156 mm.
Functional MRI
FunctionalMRIexperimentswere performed asdescribedearlier
[10–11], acquiring sets of 115 consecutive spin-echo Echo-Planar-
Images (SE-EPI;TE/TR=30/3000 ms,5 slicesof 2 mmthickness,
FOV of 25.6625.6 mm
2 covered by a 64664 matrix, i.e. an in-
plane resolutionof 400 mm). With this protocol, the total acquisition
time was 445 seconds, segmented in a fMRI paradigm of 6 resting-
state periods of 45 seconds (15 images each) and 5 intercalated
stimulation-state periods of 15 seconds (5 images each). This
paradigm was repeated typically 5 times for each forepaw, allowing
a resting period of at least 10 minutes between runs.
BOLD
BOLD functional activation imaging was achieved by electrical
stimulation of both forepaws in an alternate fashion, using
subcutaneous needle electrodes and a DC stimulation current at
intensity (2 mA, pulse length 0.3 ms; 3 Hz) below pain threshold
(STG1004 stimulator from Multi Channel Systems, Germany).
Image processing
All MRI images were processed using self-developed applica-
tions for the Image-J software platform [40–41]. For fMRI studies,
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software STIMULATE [42]. The time course of each pixel during
forepaw stimulation was examined using a paired Student’s t-test
(p,0.05). Only clusters that included at least four adjacent
activated pixels were considered as activated areas [43].
Electrophysiology
During the fMRI sessions, short latency somatosensory evoked
potentials (SSEPs) were recorded bilaterally from the primary
somatosensory cortices of the intact skull (63.5 mm lateral, 0 mm
rostro-caudal from bregma), using subcutaneously inserted steel
needle electrodes. SSEPs were constructed with DasyLab
(DATALOG, Mo ¨nchengladbach, Germany) by averaging the
signal recorded from the brain during stimulation of the paw with
100 triggered rectangular electrical pulses (2 mA;3 Hz;0.3 ms).
Recorded signal was amplified 1000-fold and filtered with a
bandpass filter between 5 and 1.000 Hz for displaying purposes.
Behavioral testing
The adhesive tape removal test was used to evaluate
sensorimotor deficits [44–45]. Two circular-shaped strips of tape
(12 mm of diameter) were applied, in random order and with
equal pressure, to the saphaneous part of the forepaws. Animals
were observed while removing the tapes in their home cages.
Latencies to contact and to remove the right and left tapes from
the paws were recorded in three trials per session. The mean time
of the three trials was calculated. At least five minutes of rest was
allowed between each trial. Healthy animals were trained daily for
3 days before baseline session, which was performed the week
before the first fMRI session (pre-scan in Fig. 1). After MCA
occlusion, behavioral tests were performed always the day prior to
the fMRI session.
Statistical analysis
Statistical analysis was performed with SPSS V15.0. All values
are expressed as mean 6 SEM, unless stated otherwise. Because of
sample sizes, statistical comparisons were performed using
Kruskal-Wallis ANOVA.
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